Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib + R2 for untreated elderly or chemotherapy-intolerant DLBCL
ChiCTR2300072551Phase 2Not yet recruiting
- Sponsor
- Henan Provincial People's Hospital
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib, lenalidomide and rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Henan Provincial People's Hospital. Primary endpoint: Progression-free survival rate. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
orelabrutiniblenalidomiderituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2300072551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072551.